AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:28 2025-06-13 am EDT			5-day change	1st Jan Change
10,986.00 ^GBX	-0.40%		+1.89%	+4.95%

Jun. 02	ASTRAZENECA : Buy rating from JP Morgan	ZD
Jun. 02	UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	RE

Trump, Starmer hail limited US-UK trade deal, but 10% duties remain

Published on 05/08/2025 at 19:40

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AstraZeneca PLC

ASTRAZENECA : Buy rating from JP Morgan	Jun. 02	ZD
UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	Jun. 02	RE
UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	Jun. 02	RE
Global markets live: Tesla, Sanofi, Apple, JPMorgan, Microsoft…	Jun. 02
AstraZeneca says Enhertu slashes disease progression risk in cancer	Jun. 02	AN
AstraZeneca Says DATROWAY Shows Promising Results in Combination Trials for Lung Cancer	Jun. 02	MT
AstraZeneca, Daiichi Sankyo's Gastric Cancer Phase 3 Trial Shows 'Statistically Significant' Improvement in Overall Survival	Jun. 02	MT
Hutchmed reports progress in late-stage lung cancer trial	Jun. 02	AN
AstraZeneca: promising results for Imfinzi in gastric cancer	Jun. 02	CF
AstraZeneca Says Imfinzi Combo Boosts Event-Free Survival in Gastric Cancer Trial	Jun. 02	MT
AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial	Jun. 02	MT
AstraZeneca: camizestrant effective in breast cancer	Jun. 02	CF
ASTRAZENECA : Receives a Buy rating from JP Morgan	Jun. 02	ZD
Stocks edge down as renewed trade tensions continue	Jun. 02	AN
AstraZeneca hails Imfinzi results on early stage gastric cancer	Jun. 02	AN
AstraZeneca's Breast Cancer Treatment Extends Progression-free Survival in Late-stage Trial	Jun. 01	MT
AstraZeneca Reports Positive Phase 3 Data for Imfinzi Regimen for Early-stage Gastric Cancer	Jun. 01	MT
PRESS DIGEST- Financial Times - June 2	Jun. 01	RE
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk	Jun. 01	RE
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk	Jun. 01	RE
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial	Jun. 01	RE
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression	May. 31	RE
FTSE 100 rises despite tariff worries; M&G shines	May. 30	AN
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools	May. 30	MT
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy	May. 30	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

Jun. 18 - J.P. Morgan European Healthcare Forum

More about the company